The p53 gene was analyzed in tumor specimens obtained from 52 patients with various types of carcinoma of the thyroid gland by a combined molecular and immunocytochemical approach. The histologic types included 37 well-differentiated papillary and follicular carcinomas, 8 poorly differentiated, and 7 undifferentiated carcinomas. The p53 gene was shown to be unaffected in all differentiated tumors by single-strand conformation polymorphism analysis. However, in two out of eight (25%) of poorly differentiated carcinomas and five out of seven (71%) undifferentiated carcinomas, p53 mutations were identified and subsequently characterized by DNA sequencing. One undifferentiated carcinoma displayed two areas with varying degrees of differentiation. The comparative analysis of the p53 gene, in both the more and the less differentiated area of this tumor, clearly showed that the p53 mutation was confined to the latter component of the tumor specimen. These results indicate that mutations of the p53 gene are associated with the most aggressive histologic types of thyroid tumors, such as the undifferentiated carcinoma and, to a certain extent, the poorly differentiated carcinoma, and that the alterations of this gene represent a late genetic event in human thyroid carcinogenesis.
R Donghi, A Longoni, S Pilotti, P Michieli, G Della Porta, M A Pierotti
Title and authors | Publication | Year |
---|---|---|
Recent advances in molecular diagnosis of thyroid cancer
I Legakis, K Syrigos |
Journal of Thyroid Research | 2011 |
Molecular genetics and diagnosis of thyroid cancer
YE Nikiforov, MN Nikiforova |
Nature Reviews Endocrinology | 2011 |
The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas
L Lavra, C Rinaldo, A Ulivieri, E Luciani, P Fidanza, L Giacomelli, C Bellotti, A Ricci, M Trovato, S Soddu, A Bartolazzi, S Sciacchitano |
PloS one | 2011 |
BRAF, p53 and SOX2 in anaplastic thyroid carcinoma
G Gauchotte, C Philippe, S Lacomme, B Léotard, MP Wissler, L Allou, B Toussaint, M Klein, JM Vignaud, A Bressenot |
Pathology | 2011 |
Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma
JH Chen, WC Faquin, RV Lloyd, V Nosé |
Modern Pathology | 2011 |
Abnormal Nuclear Structures (Micronuclei, Nuclear Blebs, Strings, and Pockets) in a Case of Anaplastic Giant Cell Carcinoma of the Thyroid: An Immunohistochemical and Ultrastructural Study
RA Caruso, F Fedele, C Crisafulli, D Paparo, A Parisi, R Lucianò, V Cavallari |
Ultrastructural Pathology | 2011 |
Thyroid Cancer
J Machac |
Thyroid Cancer | 2011 |
Well differentiated follicular thyroid neoplasia: Impact of molecular and technological advances on detection, monitoring and treatment
AG Gianoukakis, SM Giannelli, WA Salameh, LW McPhaul |
Molecular and Cellular Endocrinology | 2011 |
Poorly differentiated thyroid carcinoma in a 9-year-old boy: case report
YL Wu, WH Ting, SL Wey, CK Chen, CY Huang, SP Cheng, YJ Lee |
Journal of Pediatric Endocrinology and Metabolism | 2011 |
Gene expression profile of human thyroid cancer in relation to its mutational status
D Rusinek, S Szpak-Ulczok, B Jarzab |
Journal of Molecular Endocrinology | 2011 |
Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
P Soares, J Lima, A Preto, P Castro, J Vinagre, R Celestino, JP Couto, H Prazeres, C Eloy, V Máximo, M Sobrinho-Simões |
Current genomics | 2011 |
Cytologic and molecular diagnosis of thyroid cancers : Is it time for routine reflex testing?
LA Hassell, EM Gillies, ST Dunn |
Cancer Cytopathology | 2011 |
Poorly differentiated thyroid carcinoma: an evolving entity
G Garcia-Rostan, M Sobrinho-Simões |
Diagnostic Histopathology | 2011 |
The Loss of the p53 Activator HIPK2 Is Responsible for Galectin-3 Overexpression in Well Differentiated Thyroid Carcinomas
L Lavra, C Rinaldo, A Ulivieri, E Luciani, P Fidanza, L Giacomelli, C Bellotti, A Ricci, M Trovato, S Soddu, A Bartolazzi, S Sciacchitano, HT Nguyen |
PloS one | 2011 |